BioCardia
BCDA
19 hedge funds and large institutions have $13.5M invested in BioCardia in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 2 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
127% more capital invested
Capital invested by funds: $5.96M → $13.5M (+$7.57M)
19% more funds holding
Funds holding: 16 → 19 (+3)
0.57% more ownership
Funds ownership: 0.71% → 1.27% (+0.57%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $540K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
+$2.88M |
| 2 |
Renaissance Technologies
New York
|
+$1.27M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$624K |
| 4 |
CM
CM Management
Gulf Breeze,
Florida
|
+$346K |
| 5 |
Squarepoint
New York
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$28.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$15K |
| 3 |
Bank of New York Mellon
New York
|
-$4.56K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$3.75K |
BCDA Hedge Fund Activity: Q1 2021 in Review
19 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q1 2021, worth a combined $13.5M — up 127% from $5.96M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BCDA positions and 2 closed out — a net gain of 3 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Roumell Asset Management, adding an estimated $2.88M. The largest seller was Tower Research Capital (TRC), cutting an estimated $28.4K.
- 19 institutional investors held BioCardia (BCDA) as of Q1 2021, up from 16 in Q4 2020.
- Funds reported $13.5M of BioCardia stock for Q1 2021, up 127% quarter-over-quarter.
- 5 funds opened new BioCardia positions in Q1 2021 and 2 closed out, a net change of +3 holders.
- The largest BioCardia buyer in Q1 2021 was Roumell Asset Management, an estimated $2.88M added.
- The largest BioCardia seller in Q1 2021 was Tower Research Capital (TRC), an estimated $28.4K sold.
Based on aggregated 13F filings for Q1 2021.